Diabetic macular edema
Conditions
Interventions
Control group:Patients with persistent DME who do not respond to non-surgical treatment, in addition to conventional ophthalmic intraocular injection of anti-VEGF drugs (Conbercept) in combination wit
Experimental group:Patients with persistent DME who do not respond to non-surgical treatment, in addition to conventional ophthalmic intraocular injection of anti-VEGF drugs (Conbercept) in combinatio
Sponsors
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Retinal edema thickening in the area of 500 µm from the = fovea of the macula; with thickening of the adjacent retina; retinal thickening with at least 1 disk diameter (DD) range; 2. Age>=18 years; 3. The affected eye has received multiple anti-VEGF therapy in the past, but DME persists; or the macular foveal thickness is reduced by less than 50 µm; or the presence of epimacular membrane, showing signs of macula traction. However, the affected eye was not treated with any glass resection and macular surgery; 4. Voluntarily participate in this clinical trial and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with unclear diagnosis; 2. Patients who have had any intravitreal treatment or macular laser treatment or vitreoretinal surgery with steroids; 3. Patients with symptoms or manifestations that may be branch retinal vein occlusion; 4. Patients who refuse to participate in follow-up follow-up; 5. Those who participate in other clinical trials; 6. Any condition that, in the opinion of the investigator, needs to be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity; | — |
Countries
China
Contacts
Public ContactJin XiaoLiang
Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Outcome results
None listed